Furthermore, anemia and elevated levels of serum CEA, CA19–9 were frequently detected among 80% (28/35), 60% (21/35), 42.9% (15/35) of AFP-producing GC patients, particularly for those with serosal involvement, lymphatic and venous invasion, and lymph node metastasis. This evidence concerns the gene CEACAM5 and metastatic malignant neoplasm in the lymph nodes.